Opinion: Retool Biomedical PhD Admissions

It is unethical to admit increasing numbers of students to graduate programs without considering the realities of the job market.

Written byViviane Callier and Gary McDowell
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

FLICKR, DENISE CHANNot only is the number of biomedical PhDs in the U.S. increasing, the rate of this increase is accelerating. To justify this rapidly expanding pool of experienced biomedical scientists, some have suggested that more PhD-educated citizens are better for the country. But this is a moot point if those PhDs lack opportunities to make societal contributions utilizing their highly specialized training.

Comments like “things have always been tough” and “there are plenty of jobs” ignore the systemic problems and biases that the current generation of junior scientists face. These remarks are a distraction from the issues facing the biomedical research enterprise, many of which have been discussed in academia since before these junior scientists were born.

Defenders of the status quo point to myriad “alternative careers” and the low unemployment rate among biomedical researchers. But there is a lack of data on such trainees and their careers; the data that are available show that the number of biomedical researchers being produced is still greater than the sum of all positions for which a PhD is required—not just the academic ones. The platitude that PhDs possess diverse ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Viviane was a Churchill Scholar at the University of Cambridge, where she studied early tetrapods. Her PhD at Duke University focused on the role of oxygen in insect body size regulation. After a postdoctoral fellowship at Arizona State University, she became a science writer for federal agencies in the Washington, DC area. Now, she freelances from San Antonio, Texas.

    View Full Profile
  • The Scientist Placeholder Image
    This person does not yet have a bio.View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies